Change of Company Name

RNS Number : 0244A

Cizzle Biotechnology Holdings PLC

27 May 2021

 

27 May 2021

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Change of Company Name

Cizzle Biotechnology, a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer, is pleased to announce the Company's name has been changed to Cizzle Biotechnology Holdings plc.

As previously announced, a special resolution for the Company's name to be changed was passed by shareholders at a General Meeting of the Company on 13 May 2021.

The Company has retained its existing ticker (CIZ), SEDOL (BNG2VN0) and ISIN (GB00BNG2VN02) following the change of name.

Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes.  Any new share certificates issued will bear the new name.

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited	[phone]
John Depasquale
Alex Brearley

Novum Securities Limited	[phone]
Colin Rowbury/Jon Bellis

IFC Advisory Limited	[phone]
Tim Metcalfe
Florence Chandler

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues.  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B.  C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.

 

END

 

 

CANDKOBQOBKKAPB